Advertisement
YOU ARE HERE: LAT HomeCollectionsHoffman Laroche Inc
IN THE NEWS

Hoffman Laroche Inc

FEATURED ARTICLES
BUSINESS
June 9, 1990 | MARTHA GROVES, TIMES STAFF WRITER
Shareholders of biotechnology pioneer Genentech voted overwhelmingly Friday to approve the company's $2.1-billion merger with Roche Holding, a Swiss pharmaceutical giant, despite last-ditch efforts by disgruntled longtime investors to derail the plan. At the end of a rancorous annual meeting in Millbrae, south of San Francisco, the company said 97% of those voting favored the deal.
ARTICLES BY DATE
BUSINESS
April 20, 1993 | From Associated Press
Fifteen major U.S. and European pharmaceutical companies on Monday announced that they will share information from AIDS research efforts in an attempt to reduce drug-development time. After more than a year of formal discussions, the group, which includes Merck & Co., Pfizer Inc., Glaxo of Britain and Switzerland's Hoffman-La Roche, has agreed to exchange clinical data and drug supplies so that antiviral medicines can be tested in the best possible combinations.
Advertisement
BUSINESS
October 5, 1991 | From Times Staff and Wire Reports
Court Will Hear Eastman Kodak Suit: Cetus had argued against the Delaware Chancery Court's jurisdiction in the suit, in which Kodak is seeking to block the sale of Cetus' polymerase chain reaction technology to Hoffman-LaRoche. The $300-million sale is an integral component of Cetus' planned merger with its Emeryville, Calif., neighbor, Chiron Corp. The court's decision to hear the suit could endanger the merger.
BUSINESS
October 5, 1991 | From Times Staff and Wire Reports
Court Will Hear Eastman Kodak Suit: Cetus had argued against the Delaware Chancery Court's jurisdiction in the suit, in which Kodak is seeking to block the sale of Cetus' polymerase chain reaction technology to Hoffman-LaRoche. The $300-million sale is an integral component of Cetus' planned merger with its Emeryville, Calif., neighbor, Chiron Corp. The court's decision to hear the suit could endanger the merger.
BUSINESS
April 25, 1989 | From Associated Press
Swiss drug manufacturing giant F. Hoffmann-La Roche & Co. said Monday that it will modernize its share structure and reorganize its corporate framework. The changes would make it easier to invest in the company and conform to pending changes in Swiss corporate law. Hoffmann-La Roche failed in a takeover bid for Sterling Drug Inc. last year, and the streamlining could help the company in other U.S. takeover attempts, some analysts said. The company's U.S. operations, which accounted for $1.9 billion in revenue out of the parent's $6 billion, are based in Nutley, N.J. One school of thought holds that a global consolidation in the pharmaceutical business is inevitable.
BUSINESS
April 20, 1993 | From Associated Press
Fifteen major U.S. and European pharmaceutical companies on Monday announced that they will share information from AIDS research efforts in an attempt to reduce drug-development time. After more than a year of formal discussions, the group, which includes Merck & Co., Pfizer Inc., Glaxo of Britain and Switzerland's Hoffman-La Roche, has agreed to exchange clinical data and drug supplies so that antiviral medicines can be tested in the best possible combinations.
BUSINESS
December 1, 2006 | Molly Selvin, Times Staff Writer
Drug company agents, who say they routinely work 60-hour weeks visiting doctors' offices, said Thursday that they had sued Pfizer Inc., Johnson & Johnson and six other drug companies for failing to pay overtime. The lawsuits, which could involve tens of thousands of U.S. employees, add the pharmaceutical industry to other sectors that have been accused of giving rank-and-file workers managerial-like job titles to avoid paying overtime.
TRAVEL
March 23, 1997 | KATHLEEN DOHENY
During the first half of his semester in Africa last year, Matthew Nelson took his prescription antimalarial, mefloquine (Lariam) each week on schedule. But then the 20-year-old Pomona College student noticed some troublesome side effects and blamed them on the medicine. On Sundays, the day he took the medicine, he said he felt depressed. "I was having some stomach problems that I thought might be related," he said. Halfway through the school term, he stopped taking mefloquine and felt better.
NEWS
July 27, 1995 | TERENCE MONMANEY, TIMES MEDICAL WRITER
Perhaps heralding a leaner future for an ever-fatter America, scientists have gotten genetically obese mice to lose a third of their weight in two weeks by injecting them with a newly discovered hormone that regulates body fat. Besides studying the grotesquely obese mice, the scientists, led by Jeffrey M. Friedman, a molecular geneticist at the Howard Hughes Medical Institute and the Rockefeller University, have found a nearly identical hormone in human beings.
BUSINESS
June 9, 1990 | MARTHA GROVES, TIMES STAFF WRITER
Shareholders of biotechnology pioneer Genentech voted overwhelmingly Friday to approve the company's $2.1-billion merger with Roche Holding, a Swiss pharmaceutical giant, despite last-ditch efforts by disgruntled longtime investors to derail the plan. At the end of a rancorous annual meeting in Millbrae, south of San Francisco, the company said 97% of those voting favored the deal.
BUSINESS
April 25, 1989 | From Associated Press
Swiss drug manufacturing giant F. Hoffmann-La Roche & Co. said Monday that it will modernize its share structure and reorganize its corporate framework. The changes would make it easier to invest in the company and conform to pending changes in Swiss corporate law. Hoffmann-La Roche failed in a takeover bid for Sterling Drug Inc. last year, and the streamlining could help the company in other U.S. takeover attempts, some analysts said. The company's U.S. operations, which accounted for $1.9 billion in revenue out of the parent's $6 billion, are based in Nutley, N.J. One school of thought holds that a global consolidation in the pharmaceutical business is inevitable.
Los Angeles Times Articles
|